GSTM1 and chronic kidney disease: This analysis confirmed that potentially treatable anemia (i.e. Hb < 10 g/dL) was prevalent among patients with CKD but treated only infrequently (31.7% of the population with anemia at baseline were receiving any anemia treatment, predominantly iron replacement therapies).